Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Graier, T; Fink-Puches, R; Porkert, S; Lang, R; Pöchlauer, S; Ratzinger, G; Tanew, A; Selhofer, S; Sator, PG; Hofer, A; Gruber-Wackernagel, A; Legat, FJ; Vieyra-Garcia, PA; Quehenberger, F; Wolf, P.
Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it.
Front Med (Lausanne). 2020; 7:330-330 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Fink-Puches Regina
Graier Thomas
Gruber-Wackernagel Alexandra
Hofer Angelika
Legat Franz
Quehenberger Franz
Vieyra Garcia Pablo Augusto
Wolf Peter
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Number of Figures: 2
| |
Abstract:
Background: Little is known about psychological discomfort and quality of life (QoL) in early stage mycosis fungoides (MF) and the effect of psoralen plus UV-A (PUVA) on it. Objective: To evaluate QoL, anxiety, and depression with validated instruments in early stage MF patients and whether PUVA treatment improves it. Methods: Patients with stage IA to IIA MF were treated with PUVA twice weekly for 12-24 weeks, followed by maintenance treatment or not, in a prospective randomized clinical trial. Patients completed a questionnaire on DLQI as well as the Hospital Anxiety and Depression Scale (HADS) prior to therapy, after their last PUVA exposure, and after the PUVA maintenance or observance phase. Results: For 24 patients with early stage MF, completed questionnaires were available and analyzed. Prior to treatment, 17% reported strong (DLQI > 10) and 29% moderate impairment (DLQI 6-10) in QoL; 33% of patients reported HADS scores indicating anxiety, and 21% reported scores indicating depression. PUVA significantly improved overall QoL by reducing mean DLQI scores by 58.6% (p = 0.003), HADS-A by 30% (p = 0.045), and HADS-D by 44% (p = 0.002). Improvements in QoL and psychological well-being seemed to be sustained, irrespective of maintenance treatment or not. Limitations: Small sample size. Conclusions: PUVA sustainably improves QoL and psychological well-being in patients with early stage MF. Clinical trial registration: ClinicalTrials.gov identifier: NCT01686594. Copyright © 2020 Graier, Fink-Puches, Porkert, Lang, Pöchlauer, Ratzinger, Tanew, Selhofer, Sator, Hofer, Gruber-Wackernagel, Legat, Vieyra-Garcia, Quehenberger and Wolf.

Find related publications in this database (Keywords)
mycosis fungoides
quality of life
anxiety
depression
PUVA
phototherapy
© Med Uni Graz Impressum